Open AccessMelanotic neuroectodermal tumor of infancy successfully treated with metformin
Author(s) -
Yu Lian,
Ruicheng Tian,
Jing Wang,
Yijun Shan,
Hongxiang Gao,
Chenjie Xie,
Jingjing Li,
Lei Zhang,
Min Xu,
Song Gu
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000022303
Subject(s) - medicine , metformin , immunohistochemistry , surgery , metastasis , neural crest , pathology , cancer , embryo , insulin , biology , microbiology and biotechnology
Rationale: Melanotic neuroectodermal tumor of infancy (MNTI) is a rare tumor originated from neural crest cells with the potential for recurrence and metastasis. The peak age for the disease is during the first year after birth. The current therapy is primarily surgery. The patient reported here is the first case of MNTI treated with metformin. Patient concerns: A case of a 4-month-old infant with a history of swelling in the mouth for 1 month. Diagnosis: The tumor was diagnosed using radiology, pathology, and immunohistochemistry, and it was performed with complete surgical resection. Unfortunately, the tumor recurred 3 months after surgery. Interventions: We prescribed metformin for the infant. Outcomes: Currently, after 9 months of treatment, the tumor is well controlled without apparent side effects. Lessons: The case presented suggested that metformin may be an underlying therapy for MNTI.